Phase II trial of eribulin mesylate as a first- or second-line treatment for locally advanced or metastatic breast cancer: a multicenter, single-arm trial

被引：0
|
作者：
Tetsu Hayashida
Hiromitsu Jinno
Katsuaki Mori
Hiroki Sato
Akira Matsui
Takashi Sakurai
Hiroaki Hattori
Shin Takayama
Masahiro Wada
Maiko Takahashi
Hirohito Seki
Tomoko Seki
Aiko Nagayama
Akiko Matsumoto
Yuko Kitagawa
机构：
[1] Keio University School of Medicine,Department of Surgery
[2] Teikyo University School of Medicine,Department of Surgery
[3] Hino Municipal Hospital,Department of Surgery
[4] Mito Red Cross Hospital,Department of Surgery
[5] National Hospital Organization Tokyo Medical Center,Department of Surgery
[6] JCHO Saitama Medical Center,Division of Surgery
[7] Federation of National Public Service Personnel Mutual Aid Associations,Department of Surgery
[8] Tachikawa Hospital,Department of surgery
[9] Tokyo Dental College Ichikawa General Hospital,Department of Surgery
[10] Sanokousei general hospital,undefined
来源：
BMC Cancer | / 18卷
关键词：
Breast cancer; Eribulin; Phase II trial;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Multicenter, single-arm, phase II trial of camrelizumab and chemotherapy as neoadjuvant treatment for locally advanced esophageal squamous cell carcinoma
    Liu, Jun
    Yang, Yang
    Liu, Zhichao
    Fu, Xiaolong
    Cai, Xiaoyue
    Li, Hongxuan
    Zhu, Li
    Shen, Yan
    Zhang, Hong
    Sun, Yifeng
    Chen, Hezhong
    Yu, Bentong
    Zhang, Renquan
    Shao, Jinchen
    Zhang, Ming
    Li, Zhigang
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (03)
  • [42] Second-line therapy with pemetrexed after gemcitabine failure in patients with unresectable locally advanced or metastatic pancreatic cancer:: A multicenter phase II trial.
    Boeck, S.
    Weigang-Koehler, K.
    Fuchs, M.
    Kettner, E.
    Quietzsch, D.
    Trojan, J.
    Stötzer, O.
    Mueller, E.
    Depenbrock, H.
    Heinemann, V.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 208S - 208S
  • [43] HX008, an anti-PD1 antibody, plus irinotecan as second-line treatment for advanced gastric or gastroesophageal junction cancer: a multicenter, single-arm phase II trial
    Song, Yan
    Li, Ning
    Li, Qun
    Liang, Xinjun
    Zhang, Shu
    Fan, Qingxia
    Yin, Xianli
    Zhuang, Zhixiang
    Liu, Yunpeng
    Zhang, Jingdong
    Kou, Xiaoge
    Zhong, Haijun
    Wang, Xiaofei
    Dou, Yiwei
    Huang, Jing
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2020, 8 (02)
  • [44] Clinical effects of prior chemotherapy on eribulin: Update and subgroup analysis of phase 2 multicenter single arm study of eribulin mesylate as first-line therapy for HER2 negative locally advanced or metastatic breast cancer
    Nishimura, S.
    Takashima, T.
    Kawajiri, H.
    Kashiwagi, S.
    Noda, S.
    Tokunaga, S.
    Tei, S.
    Yamagata, S.
    Sunami, T.
    Tezuka, K.
    Ikeda, K.
    Mizuyama, Y.
    Ogawa, Y.
    Onoda, N.
    Nishimori, T.
    Ishikawa, T.
    Kudo, S.
    Takada, M.
    Hirakawa, K.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S285 - S285
  • [45] A phase II trial of second-line pemetrexed in adults with advanced/metastatic osteosarcoma
    Duffaud, Florence
    Egerer, Gerlinde
    Ferrari, Stefano
    Rassam, Hisham
    Boecker, Ulrike
    Bui-Nguyen, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 (04) : 564 - 570
  • [46] A phase II, multicenter, single-arm trial of eribulin in patients with bevacizumab-resistant recurrent glioblastoma
    Takahashi, Masamichi
    Kawashima, Satoshi
    Otake, Yohei
    Satomi-Tsushita, Natsuko
    Kuchiba, Aya
    Sadachi, Ryo
    Ohata, Keiko
    Ozawa, Hitoshi
    Yonemori, Kan
    Nagane, Motoo
    Arakawa, Yoshiki
    Mukasa, Akitake
    Tanaka, Shota
    Nishikawa, Ryo
    Muragaki, Yoshihiro
    Masutomi, Kenkichi
    Ichimura, Koichi
    Nakamura, Kenichi
    Narita, Yoshitaka
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [47] Overall survival of eribulin, trastuzumab, and pertuzumab as first-line therapy for patients with HER2-positive metastatic breast cancer: A phase II, single-arm clinical trial
    Inoue, K.
    Ninomiya, J.
    Okubo, K.
    Nakakuma, T.
    Yamada, H.
    Kimizuka, K.
    Higuchi, T.
    Saito, T.
    ANNALS OF ONCOLOGY, 2023, 34 : S1492 - S1492
  • [48] A phase II trial of docetaxel (Taxotere®) as second-line chemotherapy in patients with metastatic breast cancer
    Baur, Martina
    van Oosterom, Allan T.
    Dieras, Veronique
    Tubiana-Hulin, Michele
    Coombes, R. Charles
    Hatschek, Thomas
    Murawsky, Michael
    Klink-Alakl, May
    Hudec, Marcus
    Dittrich, Christian
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2008, 134 (02) : 125 - 135
  • [49] Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: A multicenter, single-arm phase 2 trial
    Zhao, Wensi
    Li, Liping
    Huang, Junping
    Li, Jun
    Gong, Wei
    He, Lilin
    Chen, Yuan
    Wang, Songlin
    Yu, Xiongjie
    Han, Qi
    Ke, Shaobo
    Shi, Wei
    Chen, Yongshun
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [50] The Efficacy and Safety of Anlotinib in Neoadjuvant Treatment of Locally Advanced Thyroid Cancer: A Single-Arm Phase II Clinical Trial
    Huang, Nai-si
    Wei, Wen-jun
    Xiang, Jun
    Chen, Jia-ying
    Guan, Qing
    Lu, Zhong-wu
    Ma, Ben
    Sun, Guo-hua
    Wang, Yu-long
    Ji, Qing-hai
    Wang, Yu
    THYROID, 2021, 31 (12) : 1808 - 1813
12345